Do not reconstitute in a bathroom
Additional serious warnings from FDA prescribing information: severe gastrointestinal adverse reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, hypoglycemia risk with insulin or insulin secretagogues, diabetic retinopathy and vision changes in patients with type 2 diabetes, depression or mood changes requiring clinical monitoring, and pulmonary aspiration risk during general anesthesia or deep sedation
Semaglutide mimics GLP-1, Tirzepatide targets GLP-1 and GIP, and Retatrutide is being studied for its effects on GLP-1, GIP, and glucagon receptors to support appetite control and metabolic function
These predictions say we can expect better products that reduce pain from injections
The key to safety lies in working with a trusted medical provider who can evaluate your health history, monitor your response, and make adjustments as needed
Your provider can customize your dose beyond the standard steps The goal is the lowest dose that provides steady weight loss with fewest side effects Higher dose guideline of up to 7.2 mg weekly has been approved in the U.S
